148516-11-4

Basic information

• Product Name: Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate
• Synonyms: 2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylic acid ethyl ester;ETHYL 2-CYCLOPROPYL-4-(4-FLUOROPHENYL)QUINOLINE-3-CARBOXYLATE;Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate;N-1 ETHYL-2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-QUINOLYL-3- CARBOXYLATE;3-carboxylato-2-cyclopropyl-5-ethyl-4-(4-fluorophenyl)quinolin-6-yl;3-Quinolinecarboxylic acid, 2-cyclopropyl-4-(4-fluorophenyl)-, ethyl ester;P-0
• CAS NO: 148516-11-4
• Molecular Formula: C₂₁H₁₈FNO₂
• Molecular Weight: 335.37
• Product Categories: Pitavastatin Calcium and its intermediates
• Mol File: 148516-11-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 74-76°C
• Boiling Point: 469.169 °C at 760 mmHg
• Flash Point: 237.545 °C
• Appearance: /
• Density: 1.248
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.54±0.50(Predicted)
• CAS DataBase Reference: Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate(148516-11-4)
• EPA Substance Registry System: Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate(148516-11-4)

Safety Data

• Hazardous Substances Data: 148516-11-4(Hazardous Substances Data)

Usage

General Description

Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate is a chemical compound with a complex molecular structure, composed of an ethyl group attached to a quinolyl-3-carboxylate. The compound also contains a cyclopropyl and a 4-fluorophenyl group on the quinolyl ring. It is commonly used in pharmaceutical research and drug development due to its potential biological activities and medicinal properties. This chemical may have applications in the development of new medicines for various conditions, such as bacterial or viral infections, inflammation, or cancer. Its precise mechanism of action and potential therapeutic uses would require further research and investigation.

InChI:InChI=1/C21H18FNO2/c1-2-25-21(24)19-18(13-9-11-15(22)12-10-13)16-5-3-4-6-17(16)23-20(19)14-7-8-14/h3-6,9-12,14H,2,7-8H2,1H3

Upstream product

• 3800-06-4 2-amino-4'-fluorobenzophenone 
• 24922-02-9 Ethyl 3-cyclopropyl-3-oxopropionate 
• 6311-23-5 2-(toluene-4-sulfonylamino)-benzoic acid 
• 1885-29-6 anthranilic acid nitrile 
• 1765-93-1 4-fluoroboronic acid 
• 42840-02-8 2-(Toluene-4-sulfonylamino)-benzoyl chloride 
• 118-92-3 anthranilic acid 
• 934560-46-0 N-[2-(4-fluorobenzoyl)phenyl]-4-methylbenzenesulfonamide 
• 765-43-5 Cyclopropyl methyl ketone 

Downstream Products

• 121660-37-5 2-cyclopropyl-4-(4-fluorophenyl)-3-formylquinoline 
• 148516-16-9 (1R,4S,6R)-4-{(E)-2-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-vinyl}-3,7-dioxa-bicyclo[4.1.0]heptan-2-one 
• 148516-12-5 2-Cyclopropyl-4-(4-fluoro-phenyl)-3-phenylsulfanylmethyl-quinoline 
• 148516-15-8 (6S)-6-{(E)-2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]vinyl}-5,6-dihydro-2H-pyran-2-one 
• 153968-97-9 2-cyclopropyl-4-(4-fluorophenyl)-3-iodoquinoline 
• 160375-37-1 2-Cyclopropyl-4-(4-fluoro-phenyl)-quinoline-3-carboxylic acid 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 

Relevant articles and documents

Preparation method of intermediate of pitavastatin calcium

The invention relates to a preparation method of an intermediate 2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate of pitavastatin calcium. The method comprises the following steps: with 2-aminobenzonitrile and 3-cyclopropyl-3-oxo-propionate as star

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

A series of quinoline-based 3,5-dihydroxyheptenoic acid derivatives were synthesized from quinolinecarboxylic acid esters by homologation, aldol condensation with ethyl acetoacetate dianion, and reduction of 3-hydroxyketone to evaluate their ability to inhibit the enzyme HMG-CoA reductase in vitro. In agreement with previous literature, a strict structural requirement exists on the external ring, and 4-fluorophenyl is the most active in this system. For the central ring, substitution on positions 6, 7, and 8 of the central quinoline nucleus moderately affected the potency, whereas the alkyl side chain on the 2-position had a more pronounced influence on activity. Among the derivatives, NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and improvement in potency at inhibiting HMG-CoA reductase was obtained by having the optimal substituents flanking the desmethylmevalonic acid portion, that is, 4-fluorophenyl and cyclopropyl, instead of the usual isopropyl group.

A NOVEL SYNTHETIC METHOD OF HMG-CoA REDUCTASE INHIBITOR NK-104 VIA HYDROBORATION-CROSS COUPLING SEQUENCE

The regioselective hydroboration of ethyl (3R,5S)-3,5-isopropylidenedioxy-6-heptynoate, followed by the cross-coupling reaction with an aryl halide, provides ethyl (3R,5S,6E)-7-aryl-3,5-isopropylidenedioxy-6-heptenoate, a precursor of a highly potent HMG-